Subtracting Rx Adds To Perrigo OTC Pipeline

In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."

Divesting its Rx generics business took a disproportionate amount of time considering Perrigo Company PLC’s been operating for more than 130 years and it’s been in the prescription drug space for around 15 years.

Still, with the deal with Altaris Capital Partners LLC announced on 1 March, “I don't feel like we got out at any cost,” said Perrigo president and CEO Murray Kessler....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Alliance Pharma’s New Owners Will Instill ‘More Consumer-Oriented Mindset’

22 May 2025

• By Tom Gallen

Private equity firms now in control of Alliance Pharma weighing úp plan to offload Rx business to help finance strategy to drive up sales and growth.

C&D Taps Hand Sanitizer Category With Touchland

13 May 2025

• By Malcolm Spicer

Deal totaling as much as $880m extends C&D into additional product category with a brand it says is the fastest growing in the US hand sanitizer category and No. 2 brand in the category overall.

Venture Life Focuses On CHC As It Offloads CDMO

12 May 2025

• By Tom Gallen

UK-based Venture Life is divesting its CDMO business and some non-core products to focus its attention on growing its consumer health operation.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

01 May 2025

• By Tom Gallen

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

Recordati Relying On OTC To Act As ‘Booster’ To Growth

15 May 2025

• By Tom Gallen

In categories like cough & cold and gastrointestinal, OTC products have a pivotal role to play in helping Recordati hit its sales targets for the 2025-2027 period.